Jerry Phillips - President & CEO, Drug Safety Institute

Mr. Phillips retired from the U.S. Public Health Service at the Food and Drug Administration (FDA) in 2004, after 16 years with the Agency. Joining the Agency in 1988, he became the Director of the Division of Labeling and Program Support in the Office of Generic Drugs, where he shared responsibility for the approval of all generic drugs in the U.S. In particular, he developed his expertise in the labeling and safe use of pharmaceutical products. In December of 1998, he became the Associate Director for Medication Error Prevention in the newly created Office of Post-Marketing Drug Risk Assessment (OPDRA), which is now known as the Office of Surveillance and Epidemiology (OSE).

During his 6 years with OSE, he created and became the Acting Director of the Division of Medication Errors and Technical Support (DMETS), recently renamed Division of Medication Error and Prevention Analysis (DMEPA), responsible for the review and analysis of all proprietary names in the United States. While with the OSE, he developed the methodology that the FDA uses in testing all U.S. proprietary names for safe use.

Mr. Phillips’ leadership in preventing medication errors has included work on a plethora of projects and committees stateside, including the recent Bar Coding Rule published by the FDA. In addition, he was the Chair of the Medication Errors Committee in the FDA’s Center for Drug Evaluation and Research, Chair of the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP), principal author of the Taxonomy of Medication Errors created by NCC MERP, member of NIOSH Working Group on Hazardous Drugs, and member of the Department of Defense (DoD) working group to establish pharmaceutical bar coding in the DoD.

Mr. Phillips earned his B.S. in Pharmacy from the University of Houston and completed an ASHP hospital pharmacy residency at the U.S. Public Health Service hospital in Staten Island, N.Y.

Mr. Phillips oversees all proprietary & nonproprietary strategy, naming, safety research, labeling, risk management, name submissions, rebuttals and special consults for DSI.




DSI Executive Team


Recent Healthcare Approvals

Back to top